Strategies in Acute Coronary Syndrome

Chapter

Abstract

Acute coronary syndromes include a wide spectrum of clinical coronary disease states, from unstable angina with no observable electrocardiogram changes to ST-segment elevation myocardial infarction. If not recognized and treated immediately, they may prove fatal in some cases. Percutaneous coronary intervention has emerged as a primary treatment for the majority of these patients, often on an urgent or emergency basis. Most of the interventions are ad hoc immediately following a diagnostic coronary angiogram. Understanding the details of these procedures is very important. Furthermore, knowledge of ancillary pharmacotherapy, anticoagulants, antiplatelet agents, and thrombolytics is vital in managing these patients. At times, these patients present with cardiac arrest or cardiogenic shock, which complicates management further. Intra-aortic balloon pump and Impella® devices can be used for hemodynamic support in these situations. In this chapter, we discuss the approaches for managing acute coronary syndromes, with emphasis on revascularization strategies and essential ancillary topics associated with revascularization. We also discuss the management of patients presenting with cardiogenic shock and after cardiac arrest.

References

  1. 1.
    Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;130:e344–426.CrossRefGoogle Scholar
  2. 2.
    O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127:e362–425.CrossRefGoogle Scholar
  3. 3.
    Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–98.CrossRefGoogle Scholar
  4. 4.
    Armstrong PW, Committee WS. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (which early ST-elevation myocardial infarction therapy) study. Eur Heart J. 2006;27:1530–8.CrossRefGoogle Scholar
  5. 5.
    Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379–87.CrossRefGoogle Scholar
  6. 6.
    Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31:2156–69.CrossRefGoogle Scholar
  7. 7.
    Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705–18.CrossRefGoogle Scholar
  8. 8.
    Fernandez-Aviles F, Alonso JJ, Pena G, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J. 2007;28:949–60.CrossRefGoogle Scholar
  9. 9.
    Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634–41.CrossRefGoogle Scholar
  10. 10.
    Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003;3:147–62.CrossRefGoogle Scholar
  11. 11.
    Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. Rev Esp Cardiol. 2004;57:963–80.CrossRefGoogle Scholar
  12. 12.
    Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, preventive cardiovascular nurses association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354–471.CrossRefGoogle Scholar
  13. 13.
    Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Thorac Cardiovasc Surg. 2016;152:1243–75.CrossRefGoogle Scholar
  14. 14.
    Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.CrossRefGoogle Scholar
  15. 15.
    Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141–52.CrossRefGoogle Scholar
  16. 16.
    Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet. 1996;348:1329–39.CrossRefGoogle Scholar
  17. 17.
    Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.CrossRefGoogle Scholar
  18. 18.
    Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–32.CrossRefGoogle Scholar
  19. 19.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.CrossRefGoogle Scholar
  20. 20.
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.CrossRefGoogle Scholar
  21. 21.
    Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105.CrossRefGoogle Scholar
  22. 22.
    FDA. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm
  23. 23.
    FDA. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. 2009. https://www.fda.gov/Drugs/DrugSafety/ucm231161.htm
  24. 24.
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.CrossRefGoogle Scholar
  25. 25.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.CrossRefGoogle Scholar
  26. 26.
    Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010.CrossRefGoogle Scholar
  27. 27.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefGoogle Scholar
  28. 28.
    Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.CrossRefGoogle Scholar
  29. 29.
    Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–13.CrossRefGoogle Scholar
  30. 30.
    Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553–9.CrossRefGoogle Scholar
  31. 31.
    Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.CrossRefGoogle Scholar
  32. 32.
    Task Force on the management of STEMI of the ESC, Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.CrossRefGoogle Scholar
  33. 33.
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–5.CrossRefGoogle Scholar
  34. 34.
    Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89–96.CrossRefGoogle Scholar
  35. 35.
    Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: a meta-analysis of 22 randomized trials. Thromb Res. 2015;135:902–15.CrossRefGoogle Scholar
  36. 36.
    Mina GS, Gobrial GF, Modi K, Dominic P. Combined use of bivalirudin and radial access in acute coronary syndromes is not superior to the use of either one separately: meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2016;9:1523–31.CrossRefGoogle Scholar
  37. 37.
    Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–76.CrossRefGoogle Scholar
  38. 38.
    Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.CrossRefGoogle Scholar
  39. 39.
    Karjalainen PP, Vikman S, Niemela M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J. 2008;29:1001–10.CrossRefGoogle Scholar
  40. 40.
    ASSENT-2 Investigators, Van De Werf F, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716–22.CrossRefGoogle Scholar
  41. 41.
    Rentrop P, Blanke H, Karsch KR, Kreuzer H. Coronary angiographic findings and left ventricular pump function in acute infarction and changes in the chronic stage of infarction (author's transl). Z Kardiol. 1979;68:335–50.PubMedGoogle Scholar
  42. 42.
    Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–407.CrossRefGoogle Scholar
  43. 43.
    Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947–54.CrossRefGoogle Scholar
  44. 44.
    ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569–78.CrossRefGoogle Scholar
  45. 45.
    Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–17.CrossRefGoogle Scholar
  46. 46.
    Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579–88.CrossRefGoogle Scholar
  47. 47.
    Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133:1135–47.CrossRefGoogle Scholar
  48. 48.
    Elgendy IY, Huo T, Bhatt DL, Bavry AA. Is aspiration Thrombectomy beneficial in patients undergoing primary percutaneous coronary intervention? Meta-analysis of randomized trials. Circ Cardiovasc Interv. 2015;8:e002258.CrossRefGoogle Scholar
  49. 49.
    Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587–97.CrossRefGoogle Scholar
  50. 50.
    Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389–98.CrossRefGoogle Scholar
  51. 51.
    Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol. 2013;62:1409–18.CrossRefGoogle Scholar
  52. 52.
    Gick M, Jander N, Bestehorn HP, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation. 2005;112:1462–9.CrossRefGoogle Scholar
  53. 53.
    Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063–72.CrossRefGoogle Scholar
  54. 54.
    Ndrepepa G, Kastrati A. Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. EuroIntervention. 2016;12:319–28.CrossRefGoogle Scholar
  55. 55.
    Delewi R, Hirsch A, Tijssen JG, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J. 2014;35:989–98.CrossRefGoogle Scholar
  56. 56.
    Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2012;14:91–105.CrossRefGoogle Scholar
  57. 57.
    Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb investigators. Circulation. 1998;98:1860–8.CrossRefGoogle Scholar
  58. 58.
    Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–42.CrossRefGoogle Scholar
  59. 59.
    Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291:2727–33.CrossRefGoogle Scholar
  60. 60.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.CrossRefGoogle Scholar
  61. 61.
    Mehta SR, Jolly SS, Cairns J, et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol. 2012;60:2490–9.CrossRefGoogle Scholar
  62. 62.
    Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study. J Am Coll Cardiol. 2012;60:2481–9.CrossRefGoogle Scholar
  63. 63.
    Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol. 2013;61:420–6.CrossRefGoogle Scholar
  64. 64.
    Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2013;6:814–23.CrossRefGoogle Scholar
  65. 65.
    Harada Y, Byrne RA. Bioresorbable drug-eluting stents: no pain, no gain. JACC Cardiovasc Interv. 2016;9:1228–30.CrossRefGoogle Scholar
  66. 66.
    Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting Bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–15.CrossRefGoogle Scholar
  67. 67.
    Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511–5.CrossRefGoogle Scholar
  68. 68.
    Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382:1638–45.CrossRefGoogle Scholar
  69. 69.
    Lettieri C, Savonitto S, De Servi S, et al. Emergency percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by out-of-hospital cardiac arrest: early and medium-term outcome. Am Heart J. 2009;157:569–75. e1.CrossRefGoogle Scholar
  70. 70.
    Hazinski MF, Nolan JP, Billi JE, et al. Part 1: executive summary: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation. 2010;122:S250–75.CrossRefGoogle Scholar
  71. 71.
    Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S465–82.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Texas Health Science Center Houston, Cardiology DivisionHoustonUSA

Personalised recommendations